TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04977258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill aerobic exercise without water intake
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise with water intake of a predetermined amount.
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise with water intake according to the desire to drink
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
Study: NCT04784559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Study: NCT05643651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban Oral Tablet [Xarelto]
Description: Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin or Clopidogrel
Description: Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[0.2\~1.0 mg/kg(\<2 years old),1 mg/kg(≥2 years old); once daily\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin or Clopidogrel
Description: Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[0.2\~1.0 mg/kg(\<2 years old),1 mg/kg(≥2 years old); once daily\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin 0.05\~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
Study: NCT06581484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital patient empowerment intervention
Description: The intervention has features such as a digital medical passport, updated health-related information, community support and patient/peer stories and advice
Study: NCT06583005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Coordinated Reset
Description: The Stanford CR glove is designed to administer vibrotactile coordinated reset stimulation, which consists of vibratory stimulation of the fingertips delivered in a specific pattern which is design to disrupt and normalize abnormal brain synchrony.
Study: NCT05460702

Intervention type: DIAGNOSTIC_TEST
Intervention: Soluble immune checkpoints
Description: Blood collection from breast cancer patients with stage I-II

Intervention type: DIAGNOSTIC_TEST
Intervention: Soluble immune checkpoints
Description: Blood collection from breast cancer patients with stage I-II
Study: NCT05832671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae muscle block
Description: In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
Study: NCT05970432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection 300mg-150mg
Description: TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection 600mg-300mg
Description: TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection 900mg-450mg
Description: TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH2722 injection matching Placebo
Description: Placebo without active substance.
Study: NCT05790135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shear wave elastography
Description: Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation
Study: NCT05768854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate
Description: Administered per investigator discretion via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Study: NCT05066906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Identifor assessment tool and Companion app
Description: Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to employment agencies
Description: Standard referral to employment agencies based on an individual's background, skillset, and preferences
Study: NCT06488287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (brain stimulation)
Description: The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). The 2mA continuous current will be applied during the active stimulation condition via gradual ramps that start and stop after 30 seconds of stimulation (current ramps). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Transcranial direct current stimulation (brain stimulation)
Description: The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
Study: NCT05066906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to employment agencies
Description: Standard referral to employment agencies based on an individual's background, skillset, and preferences
Study: NCT05193838

Intervention type: DRUG
Intervention: Allopurinol Tablet
Description: examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
Study: NCT05560490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroFix Cartilage P Knee Implantation
Description: The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
Study: NCT05492786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert
Description: Non-interruptive best practice alert in the electronic health record

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert
Description: Non-interruptive best practice alert in the electronic health record

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alert
Description: Non-interruptive best practice alert in the electronic health record

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salient alert features
Description: Larger alert header and body font size, use of different font colors and boldface

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salient alert features
Description: Larger alert header and body font size, use of different font colors and boldface

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-risk Text
Description: Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-risk Text
Description: Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk factors
Description: Alert body indicates the top 3 factors contributing to the high risk
Study: NCT05134415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor 1
Description: 2-week ad libitum use of the RELX ENDS tobacco flavor 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor 1
Description: 2-week ad libitum use of the RELX ENDS tobacco flavor 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor 2
Description: 2-week ad libitum use of the RELX ENDS tobacco flavor 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor 2
Description: 2-week ad libitum use of the RELX ENDS tobacco flavor 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor 1
Description: 2-week ad libitum use of the RELX ENDS menthol flavor 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor 1
Description: 2-week ad libitum use of the RELX ENDS menthol flavor 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor 2
Description: 2-week ad libitum use of the RELX ENDS menthol flavor 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor 2
Description: 2-week ad libitum use of the RELX ENDS menthol flavor 2
Study: NCT05756582

Intervention type: DIAGNOSTIC_TEST
Intervention: Prevalence of Latent Tuberculosis Infection
Description: The prevalence of Latent Tuberculosis Infection \[LTBI\] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
Study: NCT05492643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Description: all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Study: NCT06018402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy + espb
Description: the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally.
Study: NCT05492643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
Description: all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Immunity
Description: the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Immunity
Description: the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humoral Immunity
Description: the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humoral Immunity
Description: the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety
Description: all the 500 participants enrolled will undergo safety observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety
Description: all the 500 participants enrolled will undergo safety observation
Study: NCT06438432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAIT
Description: The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAIT
Description: The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.
Study: NCT05843669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guafenesin tablets
Description: During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
Study: NCT05413720

Intervention type: OTHER
Group type: OTHER
Intervention: two additional blood samples specific to research
Description: proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
Study: NCT05207891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention mattress
Description: The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
Study: NCT05040633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))
Description: Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))
Description: Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
Study: NCT05484492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: demineralized and mineralized combination putty bone allograft
Description: Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: calcium phosphosilicate putty alloplast graft
Description: Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
Study: NCT04873596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized dexmedetomidine
Description: parturient will receive nebulized 3ug/kg dexmedetomidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized midazolam
Description: parturient will receive nebulized 0.2 mg/kg midazolam.
Study: NCT06134037

Intervention type: DRUG
Intervention: Aminophylline
Description: Patients will be observationally included in the Aminophylline or not Aminiophylline group depending on anesthesiologist's discretion.
Study: NCT06458465

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: - Curcumin capsules 500 mg twice daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline 400 MG
Description: - Pentoxifylline 400 mg twice daily for 6 months.
Study: NCT05099835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolonacetonide
Description: triamcinolonacetonide stellate ganglion injection
Study: NCT05203783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie Exercises
Description: McKenzie exercises: The McKenzie set consists of 5 exercises.~1. Prone-lying~2. Prone-extension~3. Prone press ups~4. Progressive extension with pillows~5. Standing extension
Study: NCT05040633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Exercise Therapy
Description: Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Exercise Therapy
Description: Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise Therapy
Description: Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
Study: NCT05987865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: Features related to PD symptoms will be extracted from the brain recordings in real-time and used to drive a visual cursor on a computer screen placed in front of the participant, while the participant will be asked to try to control the cursor by regulating their brain signals.